EyePoint Pharmaceuticals Inc (NAS:EYPT)
$ 11.84 -0.68 (-5.43%) Market Cap: 616.68 Mil Enterprise Value: 321.95 Mil PE Ratio: 0 PB Ratio: 2.36 GF Score: 53/100

EyePoint Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference Transcript

Sep 26, 2023 / 04:25PM GMT
Release Date Price: $8 (-0.37%)
Jennifer Kim
Cantor Fitzgerald - Analyst

We're on. We're going to get started. I'm Jennifer Kim, a biopharma and biotech analyst at Cantor. And I'm looking forward to hosting EyePoint Pharmaceuticals for this fireside chat. We have with us George Elston, CFO of EyePoint .

George, thanks for joining us.

George Elston
EyePoint Pharmaceuticals, Inc. - CFO

Yeah. Thank you, Jennifer, and I appreciate the opportunity to tell the EyePoint story here at Cantor. We appreciate the invite and looking forward to the discussion.

Jennifer Kim
Cantor Fitzgerald - Analyst

Okay. Looking forward to it. Maybe to start off, can you introduce and give an overview of the company?

George Elston
EyePoint Pharmaceuticals, Inc. - CFO

Sure. So EyePoint -- we're based in Watertown, Massachusetts, and we are focused on serious eye disease, leveraging our Durasert technology, which is a well-established technology for sustained delivery of treatments to the eye.

I think we'll

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot